Global Cancer Treatment Drugs Revenue is Nearly 117 billion USD In 2017
Wednesday, 31 Oct, 2018
Global market of cancer treatment drugs developed rapidly, with an average growth rate of 7.56 In the last several years. In 2016, Global revenue of Cancer Treatment Drugs is nearly 117 billion USD.

The classification of cancer treatment drugs includes chemotherapy, targeted therapy, immunotherapy, hormonal therapy and others, and the revenue proportion of chemotherapy in 2016 is about 51%. 

Cancer treatment drugs are widely used for blood cancer, breast cancer, gastrointestinal cancer, prostate cancer, respiratory/lung cancer and other cancers. Amongst these different cancer types, blood cancer was the largest revenue generating segment in 2016, and the revenue market share is about 22%. The growth of blood cancer segment is majorly due to the high cost of the drugs used to treat blood cancer. 

Europe region is the largest supplier of cancer treatment drugs, with a revenue market share nearly 47% in 2016. North America is the second largest supplier of cancer treatment drugs, enjoying revenue market share nearly 34% in 2016. Japan region is also holding the monopoly position around the world.

North America is the largest consumption place, with the consumption market share nearly 43% in 2016, and North America market size reached 46 billion USD. China, India and Southeast Asia are the emerging markets, and enjoy higher grow rate.

Market competition is intense. Roche, Novartis, Celgene, Bristol-Myers Squibb, Amgen, Johnson & Johnson, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.